The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.
John P. Neoptolemos
No relevant relationships to disclose
William Greenhalf
No relevant relationships to disclose
Paula Ghaneh
No relevant relationships to disclose
Daniel H. Palmer
No relevant relationships to disclose
Trevor F. Cox
No relevant relationships to disclose
Elizabeth Garner
No relevant relationships to disclose
Fiona Campbell
No relevant relationships to disclose
John Robert Mackey
Other Remuneration - Clavis Pharma
Malcolm J. Moore
No relevant relationships to disclose
Juan W. Valle
No relevant relationships to disclose
Alec Mcdonald
No relevant relationships to disclose
Niall C. Tebbutt
No relevant relationships to disclose
Christos Dervenis
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Richard M. Charnley
No relevant relationships to disclose
Francois Lacaine
No relevant relationships to disclose
Julia Mayerle
No relevant relationships to disclose
Charlotte Louise Rawcliffe
No relevant relationships to disclose
Claudio Bassi
No relevant relationships to disclose
Markus W. Buchler
No relevant relationships to disclose